Does Christiana Care Health System Cover Prolia?

Understanding Who Actually Covers Prolia at ChristianaCare

ChristianaCare is a health system, not an insurance carrier. Prolia coverage decisions are made entirely by the patient's own insurance plan, whether that is Medicare, a Medicaid managed-care organization (MCO), or a commercial carrier such as Highmark, Aetna, or Cigna. ChristianaCare's role is to bill that insurer, provide the documentation needed for prior authorization, and administer the injection in a clinical setting.

Prolia (denosumab) received FDA approval in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the label was subsequently expanded to include men with osteoporosis, patients on androgen-deprivation therapy (ADT) for prostate cancer, and women on aromatase inhibitor (AI) therapy for breast cancer [1]. The drug is a RANK ligand inhibitor that reduces osteoclast activity, preserving bone mineral density (BMD) over time [2].

Because Prolia is injected by a clinician rather than self-administered at home, Medicare classifies it under Part B (medical benefit) rather than Part D (pharmacy benefit) in the vast majority of cases. That distinction matters: Part B pays 80 percent of the Medicare-allowed amount after the Part B deductible, leaving the patient responsible for the remaining 20 percent unless a Medigap or secondary plan covers that gap [3].

In the FREEDOM trial (N=7,868), denosumab reduced new vertebral fracture risk by 68 percent (relative risk reduction) over 36 months versus placebo, with a 40 percent reduction in hip fractures [4]. Those efficacy data are the clinical backbone every insurer uses when writing coverage criteria for this drug.

How Medicare Part B Covers Prolia at ChristianaCare

Medicare Part B covers Prolia when it is administered by a qualified clinician and the diagnosis code supports medical necessity. The 2024 Medicare Physician Fee Schedule lists the Healthcare Common Procedure Coding System (HCPCS) code J0897 (denosumab, 1 mg) for billing purposes; a full 60 mg dose requires 60 units [5]. The Medicare-allowed amount for a single 60 mg injection was approximately $1 to 300 in 2024 according to CMS data [5].

Covered diagnoses under most Medicare Local Coverage Determinations (LCDs) include:

• Postmenopausal osteoporosis with T-score <-2.5 at the lumbar spine or hip
• Osteoporosis in men age 50 or older with T-score <-2.5
• High fracture risk defined by a prior low-trauma (fragility) fracture
• Bone loss associated with ADT in prostate cancer or AI therapy in breast cancer
• Glucocorticoid-induced osteoporosis where other agents are contraindicated or have failed

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) clinical practice guidelines recommend pharmacologic treatment for postmenopausal women and men age 50 and older who have a hip or vertebral fracture, a T-score <-2.5 at the spine or hip, or a 10-year hip fracture probability at or above 3 percent by FRAX [6]. ChristianaCare providers typically document these FRAX scores and DEXA results in the prior authorization request.

ChristianaCare participates in Delaware's Medicaid managed-care program and accepts most major Medicare Advantage plans. For Medicare Advantage enrollees, the plan's own formulary and prior authorization rules apply rather than traditional Part B rules, so patients should confirm coverage directly with their plan before scheduling the injection.

Prior Authorization: What ChristianaCare Will Submit on Your Behalf

Prior authorization (PA) is required for Prolia by virtually every payer. ChristianaCare's specialty pharmacy and care coordination teams handle PA submission, but patients should understand what is required so delays are avoided.

A standard PA packet for Prolia includes:

1. DEXA scan results (within the prior 24 months in most plans) documenting T-score and Z-score at the lumbar spine and total hip
2. FRAX 10-year fracture probability calculated with BMD input
3. Diagnosis code (M81.0 postmenopausal osteoporosis, M81.6 localized osteoporosis, or applicable neoplasm-related code)
4. Trial and failure or contraindication documentation for first-line bisphosphonates such as alendronate (Fosamax) or risedronate (Actonel), unless the plan accepts Prolia as first-line
5. Lab results: serum calcium, vitamin D 25-OH level, and creatinine clearance. Hypocalcemia is an FDA-labeled contraindication and must be corrected before treatment begins [7]

The American Association of Clinical Endocrinology (AACE) 2020 guidelines on postmenopausal osteoporosis describe denosumab as an "appropriate second-line agent" after bisphosphonates for most patients, but designate it first-line for patients with renal impairment (CrCl <35 mL/min) where bisphosphonates are contraindicated [8]. Citing this guideline in the PA letter strengthens requests for patients with chronic kidney disease.

Approval turnaround time is typically 3 to 14 business days, though urgent clinical situations can be escalated through peer-to-peer review. Patients scheduled for an injection who do not yet have PA approval will typically have their appointment rescheduled rather than receive an unconfirmed-coverage dose.

Commercial Insurance Coverage for Prolia Through ChristianaCare

Highmark BlueCross BlueShield of Delaware, Aetna, Cigna, and United Healthcare are among the major commercial payers accepted at ChristianaCare. Each maintains its own Prolia coverage policy, but all share a common structure: medical necessity criteria, step therapy, and PA.

Aetna's Clinical Policy Bulletin for denosumab (CPB 0665) requires documentation of a T-score <-2.5 or a fragility fracture and, for most indications, a trial of at least one oral bisphosphonate [9]. Cigna's coverage policy similarly requires step-through bisphosphonate therapy for postmenopausal osteoporosis unless a documented contraindication exists.

For patients with commercial coverage, Prolia is often billed under the medical benefit when administered in the office, though some plans route it through specialty pharmacy under the pharmacy benefit. The channel matters for cost-sharing: medical-benefit cost-sharing is tied to the plan's specialist copay or coinsurance (often 20 to 30 percent of allowed cost), while pharmacy-benefit cost-sharing depends on the drug tier.

The FREEDOM Extension study followed patients for up to 10 years of continuous denosumab therapy and found sustained BMD gains at the lumbar spine (cumulative increase of 21.7 percent from baseline) with no new safety signals over time [10]. That long-term data profile helps justify ongoing PA renewals at the 12-month mark, which ChristianaCare clinicians typically document as part of annual osteoporosis management visits.

Delaware Medicaid and Prolia: Eligibility and Process

Delaware's Division of Medicaid and Medical Assistance (DMMA) covers Prolia for eligible beneficiaries through its fee-for-service program and through managed-care organizations including Highmark Health Options Delaware and Molina Healthcare of Delaware.

Medicaid fee-for-service in Delaware generally follows CMS coverage criteria: documented osteoporosis by DEXA or fragility fracture, with bisphosphonate step therapy required in most cases [11]. Managed-care Medicaid plans may apply additional utilization management criteria; ChristianaCare's care management team can contact the plan's pharmacy director directly for peer-to-peer appeals when initial requests are denied.

For dual-eligible patients (Medicare and Medicaid), Prolia is billed to Medicare Part B first. Medicaid then pays the cost-sharing remainder in most cases, leaving the patient with minimal or no out-of-pocket expense. This combination makes Prolia economically accessible for many lower-income postmenopausal patients who qualify.

Vitamin D and calcium adequacy are prerequisites for safe denosumab therapy. Current BHOF guidelines recommend 1,000 to 1 to 200 mg/day of elemental calcium from food and supplements combined, and 800 to 1 to 000 IU/day of vitamin D3 for adults at fracture risk [6]. ChristianaCare providers typically verify 25-OH vitamin D levels before each injection and supplement accordingly, as hypocalcemia risk is real and FDA-labeled [7].

What Happens If Coverage Is Denied

Coverage denials for Prolia fall into two categories: administrative (missing documentation, wrong diagnosis code, expired DEXA) and clinical (step therapy not met, T-score above threshold). ChristianaCare's care coordination team can address administrative denials quickly by resubmitting with corrected documentation.

Clinical denials warrant a formal appeal. The appeal should cite:

• BHOF guideline support for the specific indication [6]
• AACE guideline positioning of denosumab, especially for renal impairment [8]
• Published fracture reduction data from FREEDOM (68 percent relative reduction in vertebral fractures) [4]
• Any contraindication to bisphosphonate therapy (esophageal disorders, severe renal impairment, prior osteonecrosis of the jaw with oral agents)

If the first-level appeal fails, a second-level or external independent review is available under the Affordable Care Act for commercial plans. External review overturns approximately 40 percent of internal appeal denials for specialty biologics across payers, according to a 2021 analysis published in Health Affairs [12].

Patients denied coverage entirely, or facing high out-of-pocket costs, have two additional routes. First, Amgen's SupportPlus program offers a copay card that reduces commercial-plan cost-sharing to as low as $0 per injection for eligible patients [13]. Second, the Amgen Safety Net Foundation provides free Prolia to uninsured or underinsured patients who meet income criteria, with household income thresholds updated annually [13].

DEXA Scans at ChristianaCare: Getting the Foundation Right

Prolia coverage begins with an accurate dual-energy X-ray absorptiometry (DEXA) scan. ChristianaCare Health System operates bone density scanning services at multiple outpatient radiology locations across New Castle County and surrounding areas. DEXA results feed directly into the PA process and the FRAX calculation used to justify treatment.

The World Health Organization diagnostic thresholds define osteoporosis as a T-score at or below -2.5 and osteopenia as a T-score between -1.0 and -2.5 at the lumbar spine, femoral neck, or total hip [14]. Patients in the osteopenia range may still qualify for Prolia if their FRAX 10-year hip fracture probability reaches 3 percent or their major osteoporotic fracture probability reaches 20 percent, per BHOF thresholds [6].

The U.S. Preventive Services Task Force (USPSTF) recommends DEXA screening for all women age 65 and older, and for postmenopausal women under 65 whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman without additional risk factors [15]. Medicare covers DEXA scans every 24 months for beneficiaries who meet eligibility criteria, and ChristianaCare bills Medicare Part B for this service using CPT code 77080.

Sequential measurement consistency matters: the same machine, same technologist protocol, and the same scan sites should be used at each follow-up to detect meaningful change. A least significant change (LSC) of approximately 3 to 5 percent at the lumbar spine is needed to confirm a real BMD shift beyond measurement error, as outlined in the International Society for Clinical Densitometry (ISCD) 2019 Official Positions [16].

Safety Monitoring Required During Prolia Therapy

Insurers and ChristianaCare clinicians both require periodic lab monitoring during ongoing denosumab therapy. This is not optional: the FDA label includes black-box-adjacent warnings for hypocalcemia, which can be severe and fatal in patients with pre-existing hypocalcemia or severe renal impairment [7].

Required monitoring at most practices includes:

• Serum calcium before each injection (every 6 months)
• 25-OH vitamin D annually or more frequently if deficiency is suspected
• Renal function (BMP or CMP) annually, with closer monitoring in CKD patients
• Dental evaluation before starting therapy due to the rare but real risk of medication-related osteonecrosis of the jaw (MRONJ). Estimated incidence is 0 to 0.068 percent per patient-year in osteoporosis patients, substantially lower than in oncology-dose denosumab (120 mg monthly) [17]
• Atypical femoral fracture (AFF) surveillance: patients reporting new thigh or groin pain during therapy warrant femoral X-ray. AFF risk increases with duration of therapy and is estimated at approximately 3.2 to 50 per 100,000 patient-years depending on treatment duration [18]

A critical safety point specific to denosumab: therapy must not be stopped abruptly without a transition plan. Discontinuation leads to rebound bone resorption and rapid BMD loss, with vertebral fracture risk increasing significantly in the 7 to 12 months after the last dose [19]. ChristianaCare endocrinologists and rheumatologists typically transition patients to a bisphosphonate (most commonly zoledronic acid 5 mg IV annually) before stopping denosumab to preserve the BMD gains. The 2022 BHOF clinical guidance document addresses this transition directly and recommends antiresorptive bridging therapy [6].

Alternatives if Prolia Is Not Covered

If Prolia coverage is denied and appeals are exhausted, other FDA-approved osteoporosis treatments remain available. Generic alendronate (70 mg once weekly oral) costs as little as $4 to $10 per month at retail pharmacies and is covered by virtually every insurance plan without PA [20]. Risedronate (Actonel) and ibandronate (Boniva) are similarly accessible.

For patients with very high fracture risk who cannot tolerate bisphosphonates, teriparatide (Forteo, Eli Lilly) and abaloparatide (Tymlos, Radius Health) are anabolic agents that build new bone rather than only prevent resorption. Both require PA and carry higher monthly costs than bisphosphonates. Romosozumab (Evenity, Amgen/UCB), a sclerostin inhibitor approved in 2019, is another anabolic-antiresorptive option for high-risk postmenopausal women, though it carries an FDA boxed warning for cardiovascular risk and requires careful patient selection [21].

ChristianaCare's endocrinology, rheumatology, and primary care teams collaborate on individualized fracture risk management. The AACE 2020 algorithm stratifies patients into high, very high, and imminent fracture risk categories and maps each category to preferred agents [8]. Using that framework within the PA letter, and clearly documenting which tier applies to the patient, improves approval rates for Prolia and its alternatives alike.

Out-of-Pocket Cost Estimates at ChristianaCare

Understanding the likely out-of-pocket cost before the injection appointment prevents unpleasant surprises. The figures below reflect 2024 estimates and vary by plan.

• Medicare Part B with no secondary coverage: 20 percent of the approximately $1,300 allowed amount equals roughly $260 per injection, plus the Part B deductible ($240 in 2024) if not yet met [3]
• Medicare Part B plus Medigap Plan G: approximately $0 after the Part B deductible is satisfied for the year [3]
• Medicare Advantage: plan-specific; may be $0 to $200+ per injection depending on cost-sharing structure
• Commercial insurance (in-network, 20% coinsurance): approximately $100 to $400 per injection after deductible, depending on the plan's contracted rate
• Uninsured: Amgen list price exceeds $2,000 per injection; Amgen Safety Net Foundation or 340B pricing through eligible health systems may reduce this significantly [13]

ChristianaCare participates in the 340B Drug Pricing Program, which allows covered entities to purchase outpatient drugs including Prolia at substantially reduced acquisition costs. Savings generated through 340B are intended to support services for low-income and vulnerable patients, and eligible ChristianaCare patients may see lower cost estimates as a result [22].